Open for inclusion

A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype – The P[R]EBEN study

Cancer type: Lymphoma

Phase: I/II

Principal Investigator: dAmore Francesco

Country: DK

Keywords: pixantrone aggressive lymphoma, Denmark, Aarhus

Status: Open for inclusion